Dr. Reddy's ANVISA approval opens Brazil semaglutide route

Dr. Reddy's Laboratories Ltd. received Brazilian marketing authorization on November 5, 2026, for a once-weekly generic semaglutide injection for type 2 diabetes, providing access to a diabetes semaglutide market estimated at approximately US$24.46 crore for the moving annual total ended September 2026.

What did ANVISA authorize for Dr. Reddy's?

Brazil’s National Health Surveillance Agency, or ANVISA, authorized Dr. Reddy's generic semaglutide injection for adults with insufficiently controlled type 2 diabetes mellitus. The November 5, 2026 authorization covers use as an adjunct to diet and exercise, giving Dr. Reddy's a regulatory route into Brazil, which it identifies as a key Latin American market.

Dr. Reddy's said the product may be used as monotherapy when metformin is considered inappropriate because of intolerance or contraindications. It may also be used in addition to other diabetes medicines. The filing does not provide clinical-efficacy data, name the other combination treatments, or state a Brazilian price or reimbursement arrangement.

The company disclosed the approval under Regulation 30 of the Securities and Exchange Board of India’s Listing Obligations and Disclosure Requirements Regulations, 2015. The November 5 filing was addressed to the National Stock Exchange of India, BSE Limited, New York Stock Exchange Inc. and NSE IFSC Ltd., while the accompanying release set out the product’s diabetes indication.

Which semaglutide product presentations are approved in Brazil?

Dr. Reddy's said the authorized generic semaglutide will be available as a pre-filled, multi-dose injectable pen in two presentations, 2 milligrams per 1.5 millilitres and 4 milligrams per 3 millilitres. Both presentations are intended for once-weekly dosing, according to the November 2026 release.

The two approved presentations differ in their total semaglutide quantity and liquid volume, while retaining the same multi-dose pen format. Dr. Reddy's did not disclose a dose-titration schedule, individual weekly dose options, manufacturing volumes or the timing at which either 2 mg/1.5 mL or 4 mg/3 mL pens will reach Brazilian patients.

The authorized use is specifically for adults with insufficiently controlled type 2 diabetes mellitus, rather than another semaglutide indication. That distinction also applies to the company’s cited market figure of approximately US$24.46 crore, which covers semaglutide for diabetes and does not quantify any separate Brazilian market for other uses.

How large is the Brazilian diabetes opportunity cited by Dr. Reddy's?

Dr. Reddy's cited a Brazilian diabetes semaglutide market of approximately US$24.46 crore, based on IQVIA data for the moving annual total, or MAT, ended September 2026. This is the market value referenced in the authorization announcement, not a sales forecast, market-share estimate or revenue target for Dr. Reddy's.

Brazil has 16.6 million adults aged 20 to 79 living with diabetes and ranks sixth globally by the number of adults with the disease, according to the International Diabetes Federation Diabetes Atlas 2025, 11th edition, cited by Dr. Reddy's. The 16.6 million figure measures the broader diabetes population, whereas the US$24.46 crore estimate measures only the diabetes semaglutide market.

The disclosure allows a comparison between two different reference periods but not a market-growth calculation. The diabetes population statistic comes from the 2025 Diabetes Atlas, while the market-value measure covers MAT September 2026; Dr. Reddy's did not disclose an earlier market value, historical sales trend or its existing share of Brazilian semaglutide demand.

The company also did not provide expected first-year revenue, unit volumes or a commercial contribution from the 16.6 million-person diabetes population. The approval therefore establishes authorization for the two weekly pen presentations, while the cited US$24.46 crore figure indicates the size of the addressed market rather than likely sales by Dr. Reddy's.

How does Dr. Reddy's plan to launch semaglutide in Brazil?

Dr. Reddy's plans to launch semaglutide in Brazil with Aché, according to MV Ramana, Chief Executive Officer for Global Generics. The November 5, 2026 announcement names Aché as the intended launch partner but does not give a launch month, distribution arrangement, pricing plan, territorial responsibilities or financial terms.

Ramana said management’s semaglutide focus is to expand access in markets where patient need is significant, and described Brazil’s 16.6 million adults with diabetes as an important part of that strategy. This is management’s stated plan, not a confirmed commercial outcome; the company’s release says actual results, performance or events may differ from forward-looking statements.

The Brazilian authorization builds on what Dr. Reddy's calls its broader semaglutide strategy, although the release does not list other approved semaglutide markets or products. It identifies Brazil among its major markets, alongside the United States, India, Russia and Commonwealth of Independent States countries, China and Europe, and describes its product activities as including generics, branded generics, biosimilars and over-the-counter products.

The relevant product in this filing is a generic injectable diabetes medicine, rather than an active pharmaceutical ingredient or over-the-counter medicine. Its commercial pathway remains defined by two disclosed elements: ANVISA authorization for 2 mg/1.5 mL and 4 mg/3 mL pens, and management’s plan to launch the once-weekly treatment with Aché.

Conclusion

ANVISA’s November 5, 2026 authorization gives Dr. Reddy's permission to market generic semaglutide for adults with insufficiently controlled type 2 diabetes in Brazil. The company has linked the approval to an estimated US$24.46 crore diabetes semaglutide market and a broader population of 16.6 million Brazilian adults aged 20 to 79 living with diabetes, without projecting its own sales or share.

The next disclosed item to watch is the planned launch with Aché. Dr. Reddy's has not stated a launch date, price, reimbursement status or commercial terms, so future updates on the rollout of the 2 mg/1.5 mL and 4 mg/3 mL once-weekly pens would clarify how the authorization moves into market availability.